Fresh analysis suggests that individuals who discontinue popular GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds far faster than those who halt traditional lifestyle regimens.
Findings released in a major health publication shows that while overweight individuals can lose about a fifth of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing these medications must be aware of the risk of rapid weight regain when the therapy concludes," warns expert Dr. Susan Jebb.
That rate of recovery means a reversion to original weight in about a year and a half.
Analyzing Treatments
The research, which looked at dozens of trials involving thousands of patients, contrasted the results of GLP-1 agonists with conventional dieting.
Scientists emphasize that people who lose weight through diet and exercise usually see a more gradual creep back—approximately 0.1 kg a month—post-intervention.
The Reason for the Rapid Regain
Experts suggest the mode of action of the drugs accounts for the heightened regain.
These medications mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Sustained high doses of the hormone concentrations far above than the body's typical production could lead to the body to produce less of its own natural GLP-1, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication results in hunger is no longer kept in check, making overeating a significant risk."
A Chronic Disease?
The NHS suggest the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, given the high risk of relapse, the therapy should be considered long-term.
This opinion is supported by drug manufacturers, who say that the results "highlight the persistent nature of excess weight," similar to managing diseases like diabetes.
Patient Experiences
People who have discontinued the jabs explain a powerful resurgence of cravings.
"It was like something activating and I was suddenly extremely hungry," recalled an individual.
This challenge is worsened if patients have not established permanent dietary or behavioural changes during treatment.
Widespread Interest
Survey data show that millions of people in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Adoption is higher among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
Ultimately, clinicians caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone fix and maintained weight loss likely depends on combined behavioural changes.
